Becker Capital Management Inc. Sells 45,719 Shares of Sanofi $SNY

Becker Capital Management Inc. cut its holdings in shares of Sanofi (NASDAQ:SNY) by 8.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 522,681 shares of the company’s stock after selling 45,719 shares during the quarter. Becker Capital Management Inc.’s holdings in Sanofi were worth $24,671,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the business. Financial Consulate Inc. bought a new stake in Sanofi during the 3rd quarter valued at approximately $26,000. First Horizon Corp bought a new position in Sanofi in the 3rd quarter worth approximately $33,000. Salomon & Ludwin LLC grew its holdings in Sanofi by 1,046.3% during the 3rd quarter. Salomon & Ludwin LLC now owns 768 shares of the company’s stock valued at $39,000 after buying an additional 701 shares in the last quarter. Nisa Investment Advisors LLC raised its position in shares of Sanofi by 233.3% during the second quarter. Nisa Investment Advisors LLC now owns 1,000 shares of the company’s stock valued at $48,000 after buying an additional 700 shares during the last quarter. Finally, Traub Capital Management LLC purchased a new position in shares of Sanofi in the second quarter worth $51,000. Institutional investors own 14.03% of the company’s stock.

Sanofi Trading Up 0.6%

Shares of SNY opened at $48.66 on Monday. The company’s fifty day simple moving average is $47.54 and its 200-day simple moving average is $48.58. The company has a market cap of $118.68 billion, a P/E ratio of 13.52, a P/E/G ratio of 1.26 and a beta of 0.45. The company has a current ratio of 1.09, a quick ratio of 0.73 and a debt-to-equity ratio of 0.20. Sanofi has a twelve month low of $44.62 and a twelve month high of $60.12.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on SNY shares. Guggenheim cut shares of Sanofi from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 9th. Bank of America cut Sanofi from a “buy” rating to a “neutral” rating in a report on Thursday, February 12th. Barclays lowered Sanofi from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, January 6th. Weiss Ratings restated a “hold (c)” rating on shares of Sanofi in a report on Monday, December 29th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a report on Monday, December 8th. Five investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $62.67.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.